Pfizer has concluded a global licensing agreement with 3SBio, excluding China, which grants it exclusive rights for the development, production and commercialisation of 3SBio’s bispecific antibody SSGJ-707.
The antibody targets programmed cell death protein 1 and vascular endothelial growth factor and was developed using 3SBio’s CLF2 platform.
Go deeper with GlobalData
As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from Pfizer.
The agreement also includes an option for Pfizer to extend its licensing rights to include exclusive development and commercialisation of SSGJ-707 in China, for which Pfizer will pay up to $150m in option payments to 3SBio.
Pfizer research and development chief scientific officer and president Chris Boshoff stated: “We are excited to contribute our significant expertise and resources to rapidly advance the development of the SSGJ-707 programme, including novel combination strategies across a number of our major tumour areas of focus.
“This is an important candidate that combines two key targets in a promising class of medicines, complementing our antibody-drug conjugate portfolio and further demonstrating our commitment to advancing pioneering science to deliver transformative cancer medicines and new hope to people living with cancer.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSSGJ-707 is undergoing multiple clinical trials in China for metastatic colorectal cancer, non-small cell lung cancer (NSCLC) and gynaecological tumours.
Interim Phase II data have shown positive outcomes regarding the efficacy and safety of SSGJ-707 as a single agent for patients with advanced NSCLC.
Pfizer intends to manufacture the drug substance for the antibody in Sanford in the US state of North Carolina, and the drug product in Kansas.
The clinical development plan for SSGJ-707 will involve trial centres in the US and globally, with a focus on the Phase III worldwide development plan for NSCLC as well as other solid tumours.
